Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships

References

• Rowinsky EK, Chaudhry V, Cornblath DR, et al. Neurotoxicity of Taxol. J Natl Cancer Inst Monographs. 1993;15(15):107–115.
   Google Scholar
• Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: A persisting challenge in paclitaxel-based regimes. Eur J Cancer. 2006;42(1):24–30.
   PubMed Web of Science ®Google Scholar
• Simon NB, Danso MA, Alberico TA, et al. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice. Qual Life Res. 2017;26(10):2763–2772. Epub 2017 Jun 29.
   PubMed Web of Science ®Google Scholar
• Doughty CT, Seyedsadjadi R. Approach to Peripheral Neuropathy for the primary care clinician. Am J Med. 2018;131(9):1010–1016.
   PubMed Web of Science ®Google Scholar
• Bandos H, Melnikow J, Rivera DR, et al. Long-term Peripheral Neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst. 2018;110(2). DOI:10.1093/jnci/djx162
   Google Scholar
• Rivera DR, Ganz PA, Weyrich MS, et al. Chemotherapy-associated Peripheral Neuropathy in patients with early-stage breast cancer: a systematic review. J Natl Cancer Inst. 2018;110(2). DOI:10.1093/jnci/djx140
   Google Scholar
• Winters-Stone KM, Horak F, Jacobs PG, et al. Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced Peripheral Neuropathy. J Clin Oncol. 2017;35(23):2604–2612.
   PubMed Web of Science ®Google Scholar
• Shimozuma K, Ohashi Y, Takeuchi A, et al. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer. 2012;20(12):3355–3364.
   PubMed Web of Science ®Google Scholar
• Tanabe Y, Hashimoto K, Shimizu C, et al. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol. 2013;18(1):132–138. Epub 2011 Nov 22.
   PubMed Web of Science ®Google Scholar
• Eckhoff L, Knoop A, Jensen MB, et al. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer. 2015;51(3):292–300.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced Peripheral Neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;14(10):01399.
   Google Scholar
• Speck RM, Sammel MD, Farrar JT, et al. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract. 2013;9(5):e234–40.
   PubMedGoogle Scholar
• Kim WY, Woo SU, Seo JH, et al. Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases. J Cancer Res Ther. 2011;7(4):412–415.
   PubMed Web of Science ®Google Scholar
• Loibl S, Skacel T, Nekljudova V, et al. Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients’ short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. BMC Cancer. 2011;11(1):131.
   PubMedGoogle Scholar
• de Morree ES, Vogelzang NJ, Petrylak DP, et al. Association of survival benefit with docetaxel in prostate cancer and total number of cycles administered: a post hoc analysis of the mainsail study. JAMA Oncol. 2016. DOI:10.1001/jamaoncol.2016.3000.
   Web of Science ®Google Scholar
• Chan A, Hertz DL, Morales M, et al. Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. Support Care Cancer. 2019;27(10):3729–3737.
   PubMed Web of Science ®Google Scholar
• Travis LB, Fossa SD, Sesso HD, et al. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst. 2014;106(5):dju044-dju044.
   PubMedGoogle Scholar
• Krens SD, McLeod HL, Hertz DL. Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy. Pharmacogenomics. 2013;14(5):555–574.
   PubMed Web of Science ®Google Scholar
• Sun Y, Kim JH, Vangipuram K, et al. Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat. 2018;171(3):657–666.
   Web of Science ®Google Scholar
• Chen EI, Crew KD, Trivedi M, et al. Identifying predictors of taxane-induced peripheral neuropathy using mass spectrometry-based proteomics technology. PloS One. 2015;10(12):e0145816.
   PubMed Web of Science ®Google Scholar
• Jennaro TS, Fang F, Kidwell KM, et al. Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat. 2020;180(3):707–714. Epub 2020 Mar 12.
   PubMed Web of Science ®Google Scholar
• Hertz DL. Germline pharmacogenetics of paclitaxel for cancer treatment. Pharmacogenomics. 2013;14(9):1065–1084.
   PubMed Web of Science ®Google Scholar
• Tamburin S, Park SB, Alberti P, et al. Taxane and epothilone-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019;24(Suppl 2):S40–S51.
   PubMedGoogle Scholar
• Frederiks CN, Lam SW, Guchelaar HJ, et al. Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review. Cancer Treat Rev. 2015;41(10):935–950.
   PubMed Web of Science ®Google Scholar
• Cliff J, Jorgensen AL, Lord R, et al. The molecular genetics of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;120:127–140.
   PubMed Web of Science ®Google Scholar
• Molassiotis A, Cheng HL, Lopez V, et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer. 2019;19(1):132.
   PubMed Web of Science ®Google Scholar
• Dorsey SG, Kleckner IR, Barton D, et al. The national cancer institute clinical trials planning meeting for prevention and treatment of chemotherapy-induced Peripheral Neuropathy. J Natl Cancer Inst. 2019;111(6):531–537.
   PubMedGoogle Scholar
• Ioannidis JP. To replicate or not to replicate: the case of pharmacogenetic studies: have pharmacogenomics failed, or do they just need larger-scale evidence and more replication? Circ Cardiovasc Genet. 2013;6(4):413–418. discussion 8 doi.
   PubMedGoogle Scholar
• Chua KC, Kroetz DL. Genetic advances uncover mechanisms of chemotherapy-induced peripheral neuropathy. Clin Pharmacol Ther. 2017;101(4):450–452.
   PubMed Web of Science ®Google Scholar
• Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 2011;5:117–124.
   PubMed Web of Science ®Google Scholar
• van de Steeg E, van Esch A, Wagenaar E, et al. High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin Cancer Res off J Am Assoc Cancer Res. 2011;17(2):294–301.
   PubMed Web of Science ®Google Scholar
• Smith NF, Acharya MR, Desai N, et al. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther. 2005;4(8):815–818.
   PubMed Web of Science ®Google Scholar
• Nieuweboer AJ, Hu S, Gui C, et al. Influence of drug formulation on OATP1B-mediated transport of paclitaxel. Cancer Res. 2014;74(11):3137–3145. Epub 2014 Apr 22.
   PubMed Web of Science ®Google Scholar
• Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001;11(7):597–607.
   PubMedGoogle Scholar
• Shou M, Martinet M, Korzekwa KR, et al. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics. 1998;8(5):391–401.
   PubMedGoogle Scholar
• Kwak JO, Lee SH, Lee GS, et al. Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur J Pharmacol. 2010;627(1–3):92–98. Epub Nov 10.
   PubMed Web of Science ®Google Scholar
• Lagas JS, Vlaming ML, van Tellingen O, et al. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res. 2006;12(20):6125–6132.
   PubMed Web of Science ®Google Scholar
• Joerger M, Huitema ADR, van den Bongard DHJG, et al. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of paclitaxel in patients with solid tumors. Clin Cancer Res. 2006;12(7):2150–2157.
   PubMed Web of Science ®Google Scholar
• Brown T, Havlin K, Weiss G, et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol. 1991;9(7):1261–1267.
   PubMed Web of Science ®Google Scholar
• Sonnichsen DS, Hurwitz CA, Pratt CB, et al. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J clin oncol. 1994;12(3):532–538.
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Jiroutek M, Bonomi P, et al. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin Cancer Res. 1999;5(4):767–774.
   PubMed Web of Science ®Google Scholar
• Ohtsu T, Sasaki Y, Tamura T, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res. 1995;1(6):599–606.
   PubMed Web of Science ®Google Scholar
• de Graan A-JM, Elens L, Sprowl JA, et al. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res. 2013;19(12):3316–3324.
   PubMed Web of Science ®Google Scholar
• MT H, JB V, Rosing H, et al. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: A European Cancer Centre (ECC) trial. Ann Oncol. 1995;6(7):699–704.
   PubMed Web of Science ®Google Scholar
• Green H, Soderkvist P, Rosenberg P, et al. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol. 2009;104(2):130–137.
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Chaudhry V, Forastiere AA, et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol. 1993;11(10):2010–2020.
   PubMed Web of Science ®Google Scholar
• Gréen H, Söderkvist P, Rosenberg P, et al. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Vol. 104. Blackwell Publishing Inc; 2009;104(2):130–137.
   Google Scholar
• Kraff S, Lindauer A, Joerger M, et al. Excel-based tool for pharmacokinetically guided dose adjustment of paclitaxel. Ther Drug Monit. 2015;37(6):725–732.
   PubMed Web of Science ®Google Scholar
• Joerger M, Kraff S, Jaehde U, et al. Validation of a commercial assay and decision support tool for routine paclitaxel Therapeutic Drug Monitoring (TDM). Ther Drug Monit. 2017;39(6):617–624.
   PubMed Web of Science ®Google Scholar
• Mielke S, Sparreboom A, Steinberg SM, et al. Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res. 2005;11(13):4843–4850.
   PubMed Web of Science ®Google Scholar
• Xin DS, Zhou L, Li CZ, et al. TC > 0.05 as a pharmacokinetic parameter of paclitaxel for therapeutic efficacy and toxicity in cancer patients. Recent Pat Anticancer Drug Discov. 2018;13(3):341–347.
   PubMed Web of Science ®Google Scholar
• Zhang S, Sun M, Yuan Y, et al. Correlation between paclitaxel Tc > 0.05 and its therapeutic efficacy and severe toxicities in ovarian cancer patients. Cancer Trans Med. 2016;2(5):131–136.
   Google Scholar
• Hertz DL, Kidwell KM, Vangipuram K, et al. Paclitaxel plasma concentration after the first infusion predicts treatment-limiting peripheral neuropathy. Clin Cancer Res. 2018;24(15):3602–3610.
   PubMed Web of Science ®Google Scholar
• Joerger M, von Pawel J, Kraff S, et al. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2016;27(10):1895–1902.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhou F, Qi H, et al. Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer. Br J Clin Pharmacol. 2019;85(10):2292–2301.
   Web of Science ®Google Scholar
• Leblanc AF, Sprowl JA, Alberti P, et al. OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. J Clin Invest. 2018;128(2):816–825. Epub 2018 Jan 16.
   PubMed Web of Science ®Google Scholar
• Ma X, Qin X, Shang X, et al. Organic anion transport polypeptide 1b2 selectively affects the pharmacokinetic interaction between paclitaxel and sorafenib in rats. Biochem Pharmacol. 2019;169:113612. Epub Aug 19.
   PubMed Web of Science ®Google Scholar
• Fu Q, Sun X, Lustburg MB, et al. Predicting paclitaxel disposition in humans with whole-body physiologically-based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol. 2019;8(12):931–939. Epub 2019 Nov 16.
   PubMedGoogle Scholar
• Marcath LA, Pasternak AL, Hertz DL. Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications. Pharmacogenomics J. 2019;19(6):501–515. Epub 2019 Oct 15.
   PubMed Web of Science ®Google Scholar
• Bergmann TK, Brasch-Andersen C, Green H, et al. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J. 2011;11(2):113–120.
   PubMed Web of Science ®Google Scholar
• Marcath LA, Kidwell KM, Robinson AC, et al. Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure. Pharmacogenomics. 2019;20(2):95–104.
   PubMed Web of Science ®Google Scholar
• Saito Y, Katori N, Soyama A, et al. CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population. Pharmacogenet Genomics. 2007;17(7):461–471.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Fujiki Y, Kyo S, et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmacol. 2005;45(6):674–682.
   PubMed Web of Science ®Google Scholar
• Henningsson A, Marsh S, Loos WJ, et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res. 2005;11(22):8097–8104.
   PubMed Web of Science ®Google Scholar
• Marsh S, Somlo G, Li X, et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 2007;7(5):362–365.
   PubMed Web of Science ®Google Scholar
• Jiko M, Yano I, Sato E, et al. Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int J Clin Oncol. 2007;12(4):284–290.
   PubMed Web of Science ®Google Scholar
• Sissung TM, Mross K, Steinberg SM, et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer. 2006;42(17):2893–2896.
   PubMed Web of Science ®Google Scholar
• Nakajima Y, Yoshitani T, Fukushima-Uesaka H, et al. Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clin Pharmacol Ther. 2006;80(2):179–191.
   PubMed Web of Science ®Google Scholar
• Smith NF, Marsh S, Scott-Horton TJ, et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther. 2007;81(1):76–82.
   PubMed Web of Science ®Google Scholar
• Fransson MN, Gréen H, Litton J-E, et al. Influence of cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model. Drug Metab Dispos. 2011;39(2):247–255.
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Hishinuma T, Endo N, et al. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. Int J Gynecol Cancer. 2006;16(3):979–985.
   PubMed Web of Science ®Google Scholar
• de Graan AJ, Elens L, Smid M, et al. A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform. Clin Cancer Res off J Am Assoc Cancer Res. 2013;19(18):5210–5217.
   PubMed Web of Science ®Google Scholar
• Gao B, Lu Y, Nieuweboer AJM, et al. Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer. Sci Rep. 2018;8(1):1508.
   PubMedGoogle Scholar
• Sato Y, Yamamoto N, Kunitoh H, et al. Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol. 2011;6(1):132–138.
   PubMed Web of Science ®Google Scholar
• Hertz DL, Motsinger-Reif AA, Drobish A, et al. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat. 2012;134(1):401–410.
   PubMed Web of Science ®Google Scholar
• Hertz DL, Roy S, Motsinger-Reif AA, et al. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol. 2013;24(6):1472–1478.
   PubMed Web of Science ®Google Scholar
• Leskela S, Jara C, Leandro-Garcia L, et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J. 2011;11(2):121–129.
   PubMed Web of Science ®Google Scholar
• Boora GK, Kanwar R, Kulkarni AA, et al. Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance). Cancer Med. 2016;5(4):631–639.
   PubMed Web of Science ®Google Scholar
• Lam SW, Frederiks CN, van der Straaten T, et al. Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients. Br J Cancer. 2016;115(11):1335–1342.
   PubMed Web of Science ®Google Scholar
• Apellaniz-Ruiz M, Lee MY, Sanchez L, et al. Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy. Clinical cancer research: an official journal of the American Association for Cancer Research 2014; clincanres.1758.2014.
   Google Scholar
• Kus T, Aktas G, Kalender ME, et al. Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. Onco Targets Ther. 2016;9:5073–5080.
   PubMed Web of Science ®Google Scholar
• Abraham JE, Guo Q, Dorling L, et al. Replication of Genetic Polymorphisms Reported to be Associated with Taxane-Related Sensory Neuropathy in Early Breast Cancer Patients treated with Paclitaxel. 2014.
   Google Scholar
• Schneider BP, Li L, Radovich M, et al. Genome-wide association studies for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res off J Am Assoc Cancer Res. 2015;21(22):5082–5091.
   PubMed Web of Science ®Google Scholar
• Chua KC, Xiong C, Ho C, et al. Genome-wide meta-analysis validates a role for S1PR1 in microtubule targeting agent-induced sensory peripheral neuropathy. Clin Pharmacol Ther. 2020;20(10).DOI: 10.1002/cpt.1958.Online ahead of print.
   Google Scholar
• Sucheston-Campbell LE, Clay-Gilmour AI, Barlow WE, et al. Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci. Pharmacogenet Genomics. 2018;28(2):49–55.
   PubMed Web of Science ®Google Scholar
• Sucheston L, Zhao H, Yao S, et al. Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Vol. 130, Netherlands: Springer; 2011. p. 993–1002.
   Google Scholar
• Leandro-Garcia LJ, Leskela S, Jara Sanchez C, et al. Regulatory polymorphisms in beta-tubulin iia are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res. 2012;18(16):4441–4448.
   PubMed Web of Science ®Google Scholar
• Boora GK, Kulkarni AA, Kanwar R, et al. Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance). J Neurol Sci. 2015;357(1–2):35–40.
   PubMed Web of Science ®Google Scholar
• Schneider BP, Lai D, Shen F, et al. Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans. Oncotarget. 2016;7(50):82244–82253.
   PubMedGoogle Scholar
• Chen M, Wu J, Liang N, et al. Identification of a novel SBF2 frameshift mutation in charcot-marie-tooth disease type 4B2 using whole-exome sequencing. Genomics Proteomics Bioinformatics. 2014;12(5):221–227.
   PubMedGoogle Scholar
• Beutler AS, Kulkarni AA, Kanwar R, et al. Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy. Ann Neurol. 2014;76(5):727–737.
   PubMed Web of Science ®Google Scholar
• Baldwin RM, Owzar K, Zembutsu H, et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res. 2012;18(18):5099–5109.
   PubMed Web of Science ®Google Scholar
• Leandro-Garcia LJ, Inglada-Perez L, Pita G, et al. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet. 2013;50(9):599–605.
   PubMed Web of Science ®Google Scholar
• Kroetz DL, Baldwin RM, Owzar K, et al. Inherited genetic variation in EPHA5, FGD4, and NRDG1 and paclitaxel (P)-induced peripheral neuropathy (PN): results from a genome-wide association study (GWAS) in CALGB 40101. ASCO Meeting Abstracts. 2010;28(15_suppl):3021.
   Google Scholar
• Marcath LA, Kidwell KM, Vangipuram K, et al. Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy. Br J Clin Pharmacol. 2020;86(5):880–890. Epub 2020 Feb 4.
   PubMed Web of Science ®Google Scholar
• Apellaniz-Ruiz M, Tejero H, Inglada-Perez L, et al. Targeted sequencing reveals low-frequency variants in EPHA genes as markers of paclitaxel-induced peripheral neuropathy. Clin Cancer Res. 2017;23(5):1227–1235.
   PubMed Web of Science ®Google Scholar
• Chen Y, Fang F, Kidwell KM, et al. Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy. Pharmacogenomics. 2020;23(10):gs–2020.
   Google Scholar
• de Graan A-JM, Lancaster CS, Obaidat A, et al. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res. 2012;18(16):4433–4440.
   PubMed Web of Science ®Google Scholar
• Huisman MT, Chhatta AA, van Tellingen O, et al. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005;116(5):824–829.
   PubMed Web of Science ®Google Scholar
• Bardelmeijer HA, Ouwehand M, Buckle T, et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res. 2002;62(21):6158–6164.
   PubMed Web of Science ®Google Scholar
• Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J clin oncol. 1998;16(1):187–196.
   PubMed Web of Science ®Google Scholar
• SD B, Li J, AJ TT, et al. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther. 2005;77(1):43–53.
   PubMed Web of Science ®Google Scholar
• Bruno R, Olivares R, Berille J, et al. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin Cancer Res. 2003;9(3):1077–1082.
   PubMed Web of Science ®Google Scholar
• Engels FK, Loos WJ, van der Bol JM, et al. Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. Clin Cancer Res. 2011;17(2):353–362.
   PubMed Web of Science ®Google Scholar
• Fukae M, Shiraishi Y, Hirota T, et al. Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2016;78(5):1013–1023.
   PubMed Web of Science ®Google Scholar
• Sun N, Shen B, Zhu J, et al. Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study. J Transl Med. 2020;18(1):226.
   PubMed Web of Science ®Google Scholar
• Tran A, Jullien V, Alexandre J, et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther. 2006;79(6):570–580.
   PubMed Web of Science ®Google Scholar
• Baker SD, Verweij J, Cusatis GA, et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther. 2008;85(2):155–163.
   PubMed Web of Science ®Google Scholar
• Chew SC, Singh O, Chen X, et al. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. Cancer Chemother Pharmacol. 2011;67(6):1471–1478.
   PubMed Web of Science ®Google Scholar
• Chew SC, Sandanaraj E, Singh O, et al. Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients. Br J Clin Pharmacol. 2012;73(4):606–618.
   PubMed Web of Science ®Google Scholar
• Onoue H, Yano I, Tanaka A, et al. Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach. Eur J Clin Pharmacol. 2016;72(6):703–710. Epub 2016 Feb 23.
   PubMed Web of Science ®Google Scholar
• Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol. 2002;20(17):3683–3690.
   PubMed Web of Science ®Google Scholar
• Nieuweboer AJ, Smid M, de Graan AM, et al. Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics. Pharmacogenomics J. 2016;16(6):519–524. Epub Sep 8.
   PubMed Web of Science ®Google Scholar
• Fajac A, Gligorov J, Rezai K, et al. Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer. 2010;103(4):560–566. Epub 2010 Jul 13.
   PubMed Web of Science ®Google Scholar
• Zhong J, Guo Z, Fan L, et al. ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy. Thorac Cancer. 2019;10(11):2088–2095. Epub 2019 Sep 30.
   PubMed Web of Science ®Google Scholar
• Bosch TM, Huitema ADR, Doodeman VD, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res. 2006;12(19):5786–5793.
   PubMed Web of Science ®Google Scholar
• Chew SC, Lim J, Singh O, et al. Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients. Eur J Clin Pharmacol. 2014;70(2):155–166. Epub 2013 Nov 6.
   PubMed Web of Science ®Google Scholar
• Edvardsen H, Brunsvig PF, Solvang H, et al. SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance. Pharmacogenomics J. 2010;10(6):513–523. Epub Feb 16.
   PubMed Web of Science ®Google Scholar
• Lewis LD, Miller AA, Owzar K, et al. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics. 2013;23(1):29–33.
   PubMed Web of Science ®Google Scholar
• Tham L-S, Holford NHG, Hor S-Y, et al. Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4α, and constitutive androstane receptor with docetaxel pharmacokinetics. Clin Cancer Res. 2007;13(23):7126–7132.
   PubMed Web of Science ®Google Scholar
• Hor SY, Lee SC, Wong CI, et al. PXR, CAR and HNF4[alpha] genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. Pharmacogenomics J. 2007;8(2):139–146.
   PubMed Web of Science ®Google Scholar
• Sissung TM, Baum CE, Deeken J, et al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res. 2008;14(14):4543–4549.
   PubMed Web of Science ®Google Scholar
• Marsh S, Paul J, King CR, et al. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the scottish randomised trial in ovarian cancer. J Clin Oncol. 2007;25(29):4528–4535. doi25/29/4528[pii].
   PubMed Web of Science ®Google Scholar
• Eckhoff L, Feddersen S, Knoop AS, et al. Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer. Acta Oncol. 2015;54(4):535–542.
   Web of Science ®Google Scholar
• Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004;15(8):1194–1203.
   PubMed Web of Science ®Google Scholar
• Rizzo R, Spaggiari F, Indelli M, et al. Association of CYP1B1 with hypersensitivity induced by Taxane therapy in breast cancer patients. Vol. 124, Netherlands: Springer; 2010. p. 593–598.
   Google Scholar
• Mir O, Alexandre J, Tran A, et al. Relationship between GSTP1 Ile105Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann Oncol. 2009;20(4):736–740.
   PubMed Web of Science ®Google Scholar
• van Rossum AGJ, Kok M, McCool D, et al. Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy. Oncotarget. 2017;8(69):113531–113542. eCollection 2017 Dec 26.
   PubMedGoogle Scholar
• McWhinney-Glass S, Winham SJ, Hertz DL, et al. Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clin Cancer Res. 2013;19(20):5769–5776.
   PubMed Web of Science ®Google Scholar
• Hertz DL, Owzar K, Lessans S, et al. Pharmacogenetic discovery in CALGB (Alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy. Clin Cancer Res. 2016;22(19):4890–4900.
   PubMed Web of Science ®Google Scholar
• Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–417.
   PubMed Web of Science ®Google Scholar
• Elens L, van Gelder T, Hesselink DA, et al. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics. 2013;14(1):47–62.
   PubMed Web of Science ®Google Scholar
• Elens L, Nieuweboer A, Clarke SJ, et al. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics. 2013;14(2):137–149.
   PubMed Web of Science ®Google Scholar
• Huang KM, Leblanc AF, Uddin ME, et al. Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. J Clin Invest. 2020;2( 136796).
   Google Scholar
• Sprowl JA, Ciarimboli G, Lancaster CS, et al. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A. 2013;110(27):11199–11204.
   PubMed Web of Science ®Google Scholar
• Beumer JH, Chu E, Allegra C, et al. Therapeutic drug monitoring in oncology: international association of therapeutic drug monitoring and clinical toxicology recommendations for 5-fluorouracil therapy. Clin Pharmacol Ther. 2019;105(3):598–613. Epub 2018 Sep 11.
   PubMed Web of Science ®Google Scholar
• JP F, RJ G. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
   Web of Science ®Google Scholar
• Hertz DL. Concerns regarding use of patient-reported outcomes in biomarker studies of chemotherapy-induced peripheral neuropathy. Pharmacogenomics J. 2019;19(5):411–416.
   PubMed Web of Science ®Google Scholar